Eli Lilly and Company (LLY)
XETR
1,063.40
-22.40 (-2.06%)
Closed
Aug 24, 2026
Day's Range
1,056.001,079.40
52 wk Range
596.301,107.00
Financial Statements - LLY - Eli Lilly and Company
Revenue
65.17B▲ 70.8%
Net Income
20.64B▲ 130.0%Net Margin 31.7%
EBITDA
35.08B▲ 113.2%
Free Cash Flow
5.96B▲ 1598.7%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 65.17B | 38.16B | 34.12B | 28.54B | 28.31B | 24.53B |
| Cost of Goods | 11.05B | 7.13B | 7.08B | 6.62B | 7.31B | 5.48B |
| Gross Profit | 54.12B | 31.03B | 27.04B | 21.91B | 21B | 19.05B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 29.69B | 14.43B | 10.78B | 8.65B | 7.93B | 7.10B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -3.96B | -3.18B | -3.92B | -1.57B | -1.46B | 455.10M |
| Pre Tax Income | 25.73B | 10.74B | 6.55B | 6.80B | 6.15B | 7.22B |
| Income Tax | 5.09B | 1.77B | 1.31B | 561.60M | 573.80M | 1.03B |
| Net Income | 20.64B | 8.97B | 5.24B | 6.24B | 5.58B | 6.19B |
| EPS Basic | 23 | 11.798943 | 5.826687 | 6.572215 | 5.852967 | 6.47477 |
| EPS Diluted | 22.95 | 11.71 | 5.8 | 6.572215 | 5.852967 | 6.47477 |
| Basic Shares Outstanding | 897.30M | 760.58M | 938.16M | 975.63M | 979.19M | 982.21M |
| Diluted Shares Outstanding | 897.30M | 760.58M | 938.16M | 975.63M | 979.19M | 982.21M |
| Ebit | 29.69B | 11.40B | 7.04B | 7.13B | 6.49B | 7.58B |
| Ebitda | 35.08B | 16.45B | 12.45B | 10.22B | 9.55B | 8.26B |
| Net Income Continuous Operations | 20.64B | 8.97B | 5.24B | 6.24B | 5.58B | 6.19B |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
